Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Oluwayemisi Esan & Anthony S Wierzbicki. (2020) Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy. Drug Design, Development and Therapy 14, pages 2623-2636.
Read now
Read now
Articles from other publishers (28)
Undral Munkhsaikhan, Young In Kwon, Amal M. Sahyoun, María Galán, Alexis A. Gonzalez, Karima Ait-Aissa, Ammaar H. Abidi, Adam Kassan & Modar Kassan. (2023) The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr−/− Mice with Obesity. Antioxidants 12:6, pages 1287.
Crossref
Crossref
Cesare Canepari & Alessio Cantore. (2023) Gene transfer and genome editing for familial hypercholesterolemia. Frontiers in Molecular Medicine 3.
Crossref
Crossref
Shome Sankar Bhunia & Utsab Debnath. 2023. Recent Developments in Anti-Inflammatory Therapy. Recent Developments in Anti-Inflammatory Therapy
93
105
.
Ida Florance & Seenivasan Ramasubbu. (2022) Current Understanding on the Role of Lipids in Macrophages and Associated Diseases. International Journal of Molecular Sciences 24:1, pages 589.
Crossref
Crossref
Kristina Zubielienė, Gintarė Valterytė, Neda Jonaitienė, Diana Žaliaduonytė & Vytautas Zabiela. (2022) Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis. Medicina 58:11, pages 1665.
Crossref
Crossref
Yajun Duan, Ke Gong, Suowen Xu, Feng Zhang, Xianshe Meng & Jihong Han. (2022) Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Boah Lee, Seung Ju Park, Seulgi Lee, Jinwook Lee, Eunbeol Lee, Eun-Seon Yoo, Won-Suk Chung, Jong-Woo Sohn, Byung-Chul Oh & Seyun Kim. (2022) Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. Cell Death & Disease 13:7.
Crossref
Crossref
Hani Keshavarz Alikhani, Mahsa Pourhamzeh, Homeyra Seydi, Bahare Shokoohian, Nikoo Hossein-khannazer, Fatemeh Jamshidi-adegani, Sulaiman Al-Hashmi, Moustapha Hassan & Massoud Vosough. (2022) Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Angela Pirillo & Alberico Luigi Catapano. (2022) Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology 29:5, pages 829-831.
Crossref
Crossref
Richard A. Ferraro, Thorsten Leucker, Seth S. Martin, Maciej Banach, Steven R. Jones & Peter P. Toth. (2022) Contemporary Management of Dyslipidemia. Drugs 82:5, pages 559-576.
Crossref
Crossref
Niti M. Patel, Britney A. Stottlemyer, Matthew P. Gray, Richard D. Boyce & Sandra L. Kane-Gill. (2021) A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Cardiovascular Drugs and Therapy 36:2, pages 309-322.
Crossref
Crossref
Giulio Bicciato, Markus Arnold, Aidan Gebhardt & Mira Katan. (2022) Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion. Current Opinion in Neurology 35:1, pages 45-54.
Crossref
Crossref
Tatiana F. Vieira, Rita P. Magalhães, Manuel Simões & Sérgio F. Sousa. (2022) Drug Repurposing Targeting Pseudomonas aeruginosa MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations. Antibiotics 11:2, pages 185.
Crossref
Crossref
Tatiana Vieira, Rita Magalhães & Sérgio F. Sousa. (2022) Development and Validation of a Multi-Level Computational Protocol for Drug Repurposing in the Treatment of Bacterial Infections. Development and Validation of a Multi-Level Computational Protocol for Drug Repurposing in the Treatment of Bacterial Infections.
Małgorzata Bednarska-Makaruk & Agnieszka Ługowska. 2022. Cholesterol. Cholesterol
553
607
.
Karl Otfried Schwab & Jürgen DoerferKarl Otfried Schwab & Jürgen Doerfer. 2022. Pädiatrische Fettstoffwechselstörungen und Atheroskleroserisiko – kompakt. Pädiatrische Fettstoffwechselstörungen und Atheroskleroserisiko – kompakt
187
215
.
Hesham Salah El Din Taha, Hossam Kandil, Nabil Farag, Abbas Oraby, Magdy El Sharkawy, Fouad Fawzy, Hossam Mahrous, Juliette Bahgat, Mina Samy, Mohamed Aboul, Mostafa Abdrabou & Mirna Mamdouh Shaker. (2021) Egyptian practical guidance in hypertriglyceridemia management 2021. The Egyptian Heart Journal 73:1.
Crossref
Crossref
Laura D’Erasmo, Antonio Gallo, Angelo Baldassare Cefalù, Alessia Di Costanzo, Samir Saheb, Antonina Giammanco, Maurizio Averna, Alessio Buonaiuto, Gabriella Iannuzzo, Giuliana Fortunato, Arturo Puja, Tiziana Montalcini, Chiara Pavanello, Laura Calabresi, Giovanni Battista Vigna, Marco Bucci, Katia Bonomo, Fabio Nota, Tiziana Sampietro, Francesco Sbrana, Patrizia Suppressa, Carlo Sabbà, Fabio Fimiani, Arturo Cesaro, Paolo Calabrò, Silvia Palmisano, Sergio D’Addato, Livia Pisciotta, Stefano Bertolini, Randa Bittar, Olga Kalmykova, Sophie Béliard, Alain Carrié, Marcello Arca & Eric Bruckert. (2021) Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Jennifer Behbodikhah, Saba Ahmed, Ailin Elyasi, Lora J. Kasselman, Joshua De Leon, Amy D. Glass & Allison B. Reiss. (2021) Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites 11:10, pages 690.
Crossref
Crossref
Jianlin Han, Loránd Kiss, Haibo Mei, Attila Márió Remete, Maja Ponikvar-Svet, Daniel Mark Sedgwick, Raquel Roman, Santos Fustero, Hiroki Moriwaki & Vadim A. Soloshonok. (2021) Chemical Aspects of Human and Environmental Overload with Fluorine. Chemical Reviews 121:8, pages 4678-4742.
Crossref
Crossref
U.V. Chubykina, M.V. Ezhov, M.A. Saidova, T.E. Imaev, N.A. Tmoyan, P.P. Malyshev, I.A. Alekseeva, M.R. Kabardieva, A.S. Kolegaev, P.M. Lepilin, T.V. Balakhonova & V.V. Kukharchuk. (2021) Severe aortic valve stenosis with rapidly progressive atherosclerosis in a young woman with homozygous familial hypercholesterolemia: the possibilities of surgical and therapeutic treatment. Kardiologicheskii vestnik 16:2, pages 65.
Crossref
Crossref
Bhuvana Sunil, Christy Foster, Don P. Wilson & Ambika P. Ashraf. (2021) Novel therapeutic targets and agents for pediatric dyslipidemia. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882110583.
Crossref
Crossref
Mingxin Gao, Wenyuan Yu, Hui Hu, Hongli Liu, Kangjun Fan, Chengxiong Gu, Lvya Wang & Yang Yu. (2020) Case Report: Cardiac Surgery and Combined Lipid-Lowering Drug Therapy for Homozygous Familial Hypercholesterolemia. Frontiers in Pediatrics 8.
Crossref
Crossref
Anju J J Velvet, Handrean Soran, Bernard Clarke, Manish Motwani, Farzin F Ordoubadi & Matthew J Daniels. (2020) Homozygous familial hypercholesterolemia with an update on cholesterol management. Oxford Medical Case Reports 2020:9.
Crossref
Crossref
Sebastian Barata‐Vallejo & Al Postigo. (2020) New Visible‐Light‐Triggered Photocatalytic Trifluoromethylation Reactions of Carbon–Carbon Multiple Bonds and (Hetero)Aromatic Compounds. Chemistry – A European Journal 26:49, pages 11065-11084.
Crossref
Crossref
Claudia Stefanutti. (2020) Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia. Current Atherosclerosis Reports 22:8.
Crossref
Crossref
Ahmed Handhle, Adie Viljoen, Radha Ramachandran & Anthony S. Wierzbicki. (2020) Low cholesterol syndrome and drug development. Current Opinion in Cardiology 35:4, pages 423-427.
Crossref
Crossref
Michal Vrablík. (2019) Current and future trends in the treatment of dyslipidemias. Vnitřní lékařství 65:10, pages 643-650.
Crossref
Crossref